TABLE 4.
Sputum and plasma drug concentrations at 4 h postadministration on days 5 and 14
| Druga | Day | Mean (SD) concn (ng/ml) in: |
Mean (SD) ratio of all the individuals (sputum/plasma)b | |
|---|---|---|---|---|
| Sputum | Plasma | |||
| INH | 5 | 1.8 (0.6) | 1.8 (0.6) | 1.0 (0.4) |
| 14 | 1.5 (0.7) | 1.7 (0.8) | 0.9 (0.2) | |
| RIF | 5 | 1.20 (1.7) | 4.1 (1.2) | 1.0 (0.4) |
| 14 | 0.7 (0.2) | 3.9 (0.5) | 0.9 (0.2) | |
| ETM | 5 | 2.5 (2.3) | 1.6 (0.4) | 1.0 (0.4) |
| 14 | 2.0 (0.8) | 1.6 (0.3) | 0.9 (0.2) | |
| PZA | 5 | 24.1 (6.9) | 29.1 (4.9) | 1.0 (0.4) |
| 14 | 13.7 (6.3) | 25.8 (3.1) | 0.9 (0.2) | |
| TZ | 5 | 0.3 (0.3) | 11.3 (4.6) | 0.03 (0.03) |
| 14 | 0.2 (0.2) | 9.0 (4.1) | 0.03 (0.03) | |
a
INH, isoniazid; RIF, rifampin; ETM, ethambutol; PZA, pyrazinamide; TZ, tizoxanide (nitazoxanide’s active metabolite).
b
For all but TZ, data were available for n = 10 participants on days 5 and 14. For TZ, n = 18 participants at day 5, and n = 16 participants at day 14.